Crizotinib (Xalkori) for Non-Small Cell Lung Cancer

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2012年 / 54卷 / 1383期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：11 / 12
页数：2
相关论文
共 50 条
  • [1] THE USE EXPERIENCE OF CRIZOTINIB (XALKORI®) FOR POSTOPERATIVE RECURRENCE OF ALK-REARRANGED NON-SMALL CELL LUNG CANCER
    Noma, Daisuke
    Sakamoto, Kazuhiro
    Ando, Kohei
    Amano, Shinya G.
    Sudo, Shigeto
    Goto, Hideto
    Yamakawa, Yasushi
    Tsubakihara, Motofumi
    Tsuboi, Masahiro
    Masuda, Munetaka
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1320 - S1320
  • [2] Our experience with crizotinib in the treatment of non-small cell lung cancer
    Aksel, Nimet
    Gayaf, Mine
    Ari, Gulsum
    Akyol, Murat
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [3] CRIZOTINIB FOR THE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Bowles, D. W.
    Weickhardt, A. J.
    Doebele, R. C.
    Camidge, D. R.
    Jimeno, A.
    DRUGS OF TODAY, 2012, 48 (04) : 271 - 282
  • [4] Clinical use of crizotinib for the treatment of non-small cell lung cancer
    Roberts, Patrick J.
    BIOLOGICS-TARGETS & THERAPY, 2013, 7 : 91 - 101
  • [5] Crizotinib In Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Curran, Monique P.
    DRUGS, 2012, 72 (01) : 99 - 107
  • [6] XALKORI (Crizotinib) receives Approval for the Therapy of the advanced ROS1-positive non-small cell Lung Cancer (NSCLC) in the European Union (EU)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (12) : 847 - 847
  • [7] The role of brigatinib in crizotinib-resistant non-small cell lung cancer
    Mezquita, Laura
    Planchard, David
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 123 - 130
  • [8] Crizotinib-induced immunogenic cell death in non-small cell lung cancer
    Liu, Peng
    Zhao, Liwei
    Pol, Jonathan
    Levesque, Sarah
    Petrazzuolo, Adriana
    Pfirschke, Christina
    Engblom, Camilla
    Rickelt, Steffen
    Yamazaki, Takahiro
    Iribarren, Kristina
    Senovilla, Laura
    Bezu, Lucillia
    Vacchelli, Erika
    Sica, Valentina
    Melis, Andrea
    Martin, Tiffany
    Lin, Xia
    Yang, Heng
    Li, Qingqing
    Chen, Jinfeng
    Durand, Sylvere
    Aprahamian, Fanny
    Lefevre, Deborah
    Broutin, Sophie
    Paci, Angelo
    Bongers, Amaury
    Minard-Colin, Veronique
    Tartour, Eric
    Zitvogel, Laurence
    Apetoh, Lionel
    Ma, Yuting
    Pittet, Mikael J.
    Kepp, Oliver
    Kroemer, Guido
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [9] Crizotinib-induced immunogenic cell death in non-small cell lung cancer
    Peng Liu
    Liwei Zhao
    Jonathan Pol
    Sarah Levesque
    Adriana Petrazzuolo
    Christina Pfirschke
    Camilla Engblom
    Steffen Rickelt
    Takahiro Yamazaki
    Kristina Iribarren
    Laura Senovilla
    Lucillia Bezu
    Erika Vacchelli
    Valentina Sica
    Andréa Melis
    Tiffany Martin
    Lin Xia
    Heng Yang
    Qingqing Li
    Jinfeng Chen
    Sylvère Durand
    Fanny Aprahamian
    Deborah Lefevre
    Sophie Broutin
    Angelo Paci
    Amaury Bongers
    Veronique Minard-Colin
    Eric Tartour
    Laurence Zitvogel
    Lionel Apetoh
    Yuting Ma
    Mikael J. Pittet
    Oliver Kepp
    Guido Kroemer
    Nature Communications, 10
  • [10] Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer
    Miao, Kang
    Zhang, Xiaotong
    Wang, Hanping
    Si, Xiaoyan
    Zhang, Li
    THORACIC CANCER, 2023, 14 (13) : 1162 - 1170
12345